Although various AHR agonists, including TCDD, FICZ, and Bap, have demonstrated therapeutic potential in in vitro models, their use can lead to severe complications such as liver fibrosis [23], embryo mortality [24] and carcinogenesis [25]. This evidence concerns the gene AHR and Hepatic fibrosis.